Kratom injury lawsuits have emerged as a significant area of product liability litigation, with victims and their families seeking compensation for deaths and serious injuries allegedly caused by the botanical supplement. In recent years, plaintiffs have won substantial verdicts against kratom manufacturers, including an $11 million judgment in Florida for the death of Krystal Talavera, who collapsed and died in 2021 after consuming a kratom product called “space dust”—with her autopsy confirming acute mitragynine intoxication as the cause of death.
These cases represent a growing recognition that kratom, widely marketed as a safe natural alternative for pain relief and energy, carries serious health risks that manufacturers have failed to adequately disclose to consumers. The litigation landscape for kratom injuries has accelerated dramatically since 2023, with multiple wrongful death verdicts, class action filings, and regulatory action from the FDA. Injured parties now face a fragmented legal system where cases are being pursued individually across state and federal courts rather than consolidated under a single mass tort program, making it important to understand your legal options and the precedents that have been established.
Table of Contents
- What Are Kratom Injury Lawsuits and Who Is Filing Them?
- Major Kratom Verdicts and Settlements to Date
- Recent Litigation: 2024–2026 Cases and Ongoing Disputes
- The Role of FDA Action and Regulatory Developments
- Why There Is No Nationwide Settlement or MDL Yet
- What Types of Injuries Are Covered in Kratom Lawsuits?
- The Future of Kratom Litigation and What Injured Parties Should Know
- Conclusion
What Are Kratom Injury Lawsuits and Who Is Filing Them?
Kratom injury lawsuits are product liability claims filed by consumers, families of deceased users, and their representatives against kratom manufacturers and sellers. These lawsuits allege that kratom products—particularly those containing concentrated forms of mitragynine or 7-hydroxymitragynine (7-OH)—have caused serious harm, including death, organ damage, and severe medical emergencies. Plaintiffs typically allege two core failures by defendants: failure to warn consumers about the risks of kratom use and failure to exercise reasonable care in manufacturing products known to be dangerous. The profile of kratom injury claimants varies widely.
Some are chronic pain patients who turned to kratom as an alternative to opioids, seeking relief from conditions like arthritis or back injuries. Others are individuals struggling with addiction who used kratom as a purported way to manage withdrawal symptoms. Many cases involve young adults who consumed kratom recreationally without understanding its potency or potential for serious adverse effects. What unites these plaintiffs is that they or their loved ones experienced severe consequences—seizures, respiratory failure, organ damage, or death—that they attribute directly to kratom product use.
Major Kratom Verdicts and Settlements to Date
Two landmark verdicts have set important precedents in kratom litigation. In 2023, Washington State delivered a $2.5 million wrongful death verdict—the first kratom wrongful death trial to reach a jury. This case involved Patrick Coyne, who died of acute mitragynine intoxication from a product called “Kratom Divine.” The jury found the manufacturer liable, establishing that kratom-related deaths could meet the legal threshold for product liability in at least one jurisdiction and demonstrating that manufacturers could be held accountable for failing to warn consumers about lethal risks. The $11 million Florida verdict was far more substantial and involved particularly sympathetic facts.
Krystal Talavera, a 34-year-old woman, collapsed and died in 2021 after consuming a kratom product. An autopsy confirmed that acute mitragynine intoxication directly caused her death. The substantial jury award underscored the gravity of kratom-related harms and signaled to other injured parties and their attorneys that significant compensation might be available. However, these verdicts also revealed a critical limitation: there is currently no nationwide MDL (Multi-District Litigation) or global settlement program for kratom claims, meaning injured parties must pursue cases individually or through scattered class actions rather than benefiting from consolidated proceedings.
Recent Litigation: 2024–2026 Cases and Ongoing Disputes
The volume of kratom litigation has accelerated sharply in recent years. At least 15 class action lawsuits were filed against major kratom manufacturers in 2024 alone, indicating growing legal momentum and raising the stakes for companies in the industry. These cases allege similar theories: that manufacturers market kratom as safe despite knowing—or should have known—about serious health risks, and that they fail to provide adequate warnings on product labels. In February 2024, a significant wrongful death complaint was filed in Matthew J.
Torres’s estate lawsuit, alleging that his death from seizures and convulsions was directly caused by the toxic effects of mitragynine. In Colorado, Robert Simmons’s wrongful death case, filed in September 2024, targets major kratom manufacturers on theories of failure to disclose risks and inadequate warning labels. Most recently, in March 2026, a federal court in Louisiana issued a mixed ruling on a motion to dismiss a kratom wrongful death and product liability case involving OPMS kratom products, partly denying the motion and allowing claims for unreasonably dangerous product design and inadequate warnings to proceed. This ruling suggests that kratom manufacturers face significant exposure in federal court, despite their efforts to dismiss cases early in litigation.
The Role of FDA Action and Regulatory Developments
Until recently, the FDA largely took a hands-off approach to kratom regulation, treating it as a dietary supplement even though it is not a pharmaceutical drug. This regulatory gap left consumers vulnerable, as kratom products were sold without the warning labels, efficacy claims review, or safety testing required for drugs. However, the FDA has begun taking action—specifically targeting concentrated forms of mitragynine and 7-hydroxymitragynine (7-OH) products.
In July 2025, the FDA issued warning letters to companies marketing 7-hydroxymitragynine products and announced a recommendation to schedule certain 7-OH products under the Controlled Substances Act. Importantly, the FDA clarified that natural kratom leaf products were not the primary target of this action. This regulatory distinction matters for litigation: it suggests that concentrated and processed kratom derivatives pose greater recognized risks, potentially strengthening claims against manufacturers who sold highly concentrated forms or who marketed 7-OH products without adequate disclosure. From a consumer perspective, this means that products labeled as “kratom leaf” differ significantly from refined extracts, and manufacturers of the latter face heightened scrutiny.
Why There Is No Nationwide Settlement or MDL Yet
Unlike many mass tort situations—such as opioid litigation, talc-related cancer claims, or defective medical device injuries—kratom injury cases have not been consolidated into a nationwide MDL. This creates a mixed landscape for injured parties. On one hand, the lack of centralization means that verdicts in favorable jurisdictions like Florida and Washington serve as powerful precedents without being diluted by unfavorable rulings elsewhere. On the other hand, the absence of a global settlement mechanism means there is no streamlined path to compensation for all injured parties, and pursuing claims requires finding an attorney willing to litigate individually or joining a scattered class action. The reasons for the lack of an MDL are multifaceted.
First, kratom litigation is still relatively young compared to other mass torts—the major verdicts came in 2023 and 2024. Second, kratom manufacturers have mounted aggressive defenses, arguing that kratom is a traditional herbal product with a long history of use and that individual cases involve confounding factors (other drug use, pre-existing conditions). Third, many cases are being pursued in state courts, which may not be consolidated under federal MDL procedures. A key limitation to understand: if you suffered a kratom injury, you may not be able to participate in a large-scale settlement and instead may need to either pursue your own claim or join one of the scattered class actions. This means outcomes can vary significantly depending on your jurisdiction and the specific attorney or firm handling your case.
What Types of Injuries Are Covered in Kratom Lawsuits?
Kratom lawsuits cover a wide range of injuries, from fatal outcomes to serious non-fatal harms. Wrongful death cases—like those involving Krystal Talavera and Patrick Coyne—represent the most severe category and have garnered the highest verdicts. These cases typically involve acute mitragynine intoxication leading to seizures, respiratory failure, cardiac events, or other fatal complications. However, kratom injury claims also encompass serious non-fatal injuries, including liver damage, kidney injury, respiratory distress, seizures, psychosis, and severe withdrawal syndromes when users attempt to stop using kratom after developing dependence.
The specificity of the claimed injury matters in litigation. A plaintiff who can point to medical documentation of kratom use immediately preceding a medical emergency, combined with an autopsy or medical record showing mitragynine presence, has a stronger case than someone alleging general “kratom-related health problems” without acute causation. This is why the landmark verdicts involved clear causal chains: documented kratom consumption, rapid onset of severe symptoms, and medical confirmation of mitragynine’s role. For injured parties considering a claim, having thorough medical records, hospital documentation, and ideally toxicology reports strengthens your position.
The Future of Kratom Litigation and What Injured Parties Should Know
The trajectory of kratom litigation suggests that claims will likely continue to increase, particularly if the FDA follows through on scheduling certain 7-OH products or if additional regulatory restrictions are implemented. The combination of established precedent (major verdicts), regulatory scrutiny, and growing public awareness of kratom’s risks has created conditions favorable to future litigation. However, the absence of a nationwide settlement means the legal landscape will remain fragmented for the foreseeable future.
For injured parties, the key takeaway is that your right to compensation depends heavily on your jurisdiction, the specific kratom product involved, and whether you can establish a clear causal link between kratom use and injury. The cases won so far have involved documented kratom consumption and severe acute medical events. If you have suffered a kratom-related injury, consulting with a product liability attorney who has experience with kratom cases—particularly those familiar with the landmark verdicts in Florida and Washington—is critical to understanding your legal options and the realistic timeline and compensation you might expect.
Conclusion
Kratom injury lawsuits represent an evolving area of product liability law in which consumers and families harmed by kratom products have already won significant verdicts and continue to file new claims. The $11 million Florida verdict, the $2.5 million Washington State verdict, and the numerous cases filed in 2024 and 2025 demonstrate that manufacturers face real legal exposure for failing to warn consumers about kratom’s serious health risks. FDA regulatory action targeting concentrated forms of kratom further indicates that the risks associated with these products are increasingly recognized by government agencies.
If you have suffered a serious injury or the loss of a loved one due to kratom use, you have legal options—but the path to compensation is not yet centralized through a nationwide settlement program. Instead, claims are being pursued through individual lawsuits and scattered class actions across multiple jurisdictions. The strength of your potential claim will depend on factors including your location, the specific product involved, and the medical evidence linking kratom use to your injury. Consulting with an experienced product liability attorney is the essential first step to understanding your rights and options.